Detection of antibodies against Actinobacillus pleuropneumoniae serotype 5 using an inhibition enzyme immunoassay.

An inhibition enzyme immunoassay (EIA) for detection of antibodies against A. pleuropneumoniae serotype 5 (App-5) in pig sera, based on the inhibition of the binding of an App-5 specific monoclonal antibody was established. The monoclonal antibody (MAb 210-F11) was found to be directed against an epitope on the O-chain of App-5 LPS. In the inhibition EIA, highly purified App-5 LPS was used to coat microtitre plates. Serial dilutions of pig sera were added to the plates prior to the addition of the MAb 210-F11. The degree of binding of App-5 antibodies from pig sera was determined as the percentage inhibition of the MAb 210-F11. Pig serum from specific pathogen free (SPF) herds, from experimentally infected animals, and from acutely and chronically infected herds were tested. A serum dilution of 1/30 was found to be optimal, when using 50% inhibition as the discriminating inhibition percentage. No cross-reactivity was observed with serum from pigs infected with other App serotypes or bacteria isolated from the respiratory tract, such as A. suis and H. parasuis. The inhibition EIA will be used for surveillance of App-5 antibodies in SPF and conventional herds.

Detection of an Actinobacillus pleuropneumoniae serotype 2 lipopolysaccharide (LPS) variant.

Until now 12 serotypes of Actinobacillus pleuropneumoniae have been recognized. The specificity of the serotypes reside in the carbohydrate composition of the capsular polysaccharides and lipopolysaccharides (LPS). The LPS of A. pleuropneumoniae serotype 2 is a smooth type LPS with O-chains of linear repeating pentasaccharide units with an O-acetyl group linked to a glucose unit. A monoclonal antibody (MAb 102-G02) directed against A. pleuropneumoniae serotype 2 was characterized in enzyme linked immunosorbent assay (ELISA) and in sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). The MAb 102-G02 was directed against an epitope on the O-chain of the LPS and was used to define a new. LPS variant of A. pleuropneumoniae serotype 2 (referred to as A. pleuropneumoniae serotype 2X). Investigation of the reactivity of the MAb 102-G02 against an A. pleuropneumoniae serotype 2X, field isolate (9008) and the Danish App-2 strain 4226 in electron microscopy, confirmed the different binding patterns.

Serotyping of Actinobacillus pleuropneumoniae serotype 5 strains using a monoclonal-based polystyrene agglutination test.

A polystyrene agglutination test has been developed for serotyping Actinobacillus pleuropneumoniae serotype 5a and 5b strains. Protein A-coated polystyrene microparticles were sensitized with a murine monoclonal antibody recognizing an epitope on serotype 5 LPS-O chain as shown by SDS-PAGE and Western blotting. A total of 205 A. pleuropneumoniae, strains including all 12 serotype reference strains and 13 strains representing 8 common bacterial species associated with swine or related to A. pleuropneumoniae, were tested by mixing 25 microL of polystyrene reagent with the same volume of a dense suspension of bacterial cells grown for 18 h. All A. pleuropneumoniae strains had been previously serotyped using standard procedures. The polystyrene agglutination test was rapid (less than 3 min) and easy to perform. Overall a very good correlation (97.3%) with the standard techniques was found. The sensitized polystyrene particles were stable for at least 6 mo.

Production and characterization of monoclonal antibodies against Actinobacillus pleuropneumoniae serotype 1.

Three monoclonal antibodies (mAbs) against Actinobacillus pleuropneumoniae serotype 1, designated 4.2 A11 B5, 5.1 G8 F10 and 1.5 C5 F4 (IgG3, IgG2b and IgM respectively), were produced and characterized. mAbs 4.2 A11 B5 and 5.1 G8 F10 were directed against different epitopes located in the O chain of the LPS. Both clones also recognized reference strains of A. pleuropneumoniae serotypes 9 and 11. The mAb 1.5 C5 F4 reacted with the reference strain of A. pleuropneumoniae serotype 1, with the encapsulated strain 4045 (but not with its non-capsulated mutant) and with A. pleuropneumoniae serotype 1 purified capsular polysaccharides (CPS). The epitope was sensitive to periodate oxidation, heat-labile, and located in the capsular material of A. pleuropneumoniae serotype 1, as demonstrated by immunoblotting. Treatment of the CPS with 5% ammonium hydroxide eliminated the reaction, which may indicate that the epitope recognized by 1.5 C5 F4 mAb is a O-acetyl containing determinant. When different A. pleuropneumoniae field strains were tested, the percentage of strains recognized by the mAbs varied with the mAb and the test used. Cross-reactions associated with the LPS of some A. pleuropneumoniae serotype 5 field strains could be observed with the 4.2 A11 B5 mAb. Of the three mAbs characterized, 1.5 C5 F4 seemed to be the most suitable for A. pleuropneumoniae serotype 1 detection since it reacted with 99% of serotype 1 field strains and it did not recognize any of the strains belonging to other serotypes.

Detection of Actinobacillus pleuropneumoniae serotype 2 antibodies in pig sera by an inhibition enzyme immuno assay (EIA).

An inhibition Enzyme Immuno Assay (EIA) for detection of antibodies against A. pleuropneumoniae serotype 2 (App-2) in pig sera, based on the inhibition of the binding of an App-2 specific monoclonal antibody was established. The monoclonal antibody (mAb 102-G02) was found to be directed against an epitope on the O-chain of App-2 LPS. Some App-2 isolates did not react with the mAb 102-G02. These isolates are referred to as App-2X. In the inhibition EIA highly purified App-2 LPS ws used to coat microtiter plates. Serial dilutions of pig sera were added to the plates prior to the mAb 102-G02. The degree of binding of App-2 antibodies from pig sera was determined as the percentage inhibition of the mAb 102-G02. Pig sera from specific pathogen free (SPF) herds, from experimentally infected animals, and from conventionel herds were tested. A serum dilution of 1/200 was found to be optimal, when using 50% inhibition as the discriminating inhibition percentage. Serum from App-2X infected herds showed a lower reactivity as compared to serum from App-2 infected herds. No crossreactivity was observed with serum from pigs infected with other App serotypes. The sensitivity and specificity were 100% and 98.9%, respectively.

Use of passive immunization for the production of monoclonal antibodies against Actinobacillus pleuropneumoniae serotype 1,6 and 12.

Hyperimmune sera from BALB/c mice immunized intraperitoneally (IP) with Actinobacillus pleuropneumoniae serotype 2 were used for passive intraperitoneal (i.p.) immunization of BALB/c mice. The immunized mice were subsequently immunized i.p. with a mixture of A. pleuropneumoniae serotypes 1, 6 and 12. Numerous monoclonal antibodies specific for serotypes 1, 6 and 12 were obtained. Using this immunization scheme antibodies can be obtained against specific antigens from closely related bacteria.

Human complement component C2: production and characterization of polyclonal and monoclonal antibodies against C2.

Rabbit antibodies to human complement component C2 were produced by immunization of rabbits with precipitates from line immunoelectrophoresis, and the antibodies were used to monitor a classical chromatographic purification of C2 and for affinity purification of C2. Twelve monoclonal antibodies with specificity for human complement component C2 were produced by fusion of myeloma cells with spleen cells from mice immunized with the affinity purified C2. The specificity of the monoclonal antibodies was confirmed by their reaction with antigen-antibody precipitates where C2 was the antigen, and by their specific reaction with C2 after separation in SDS-PAGE followed by immunoblotting. The affinity of the monoclonal antibodies varied as demonstrated by the titration curves in ELISA. The antibodies will be of importance for immunospecific purification of human C2 and C2 fragments, for specific depletion of C2 from human serum, and for quantification of C2 for clinical purposes.